Surgery is usually the first move against cutaneous squamous cell carcinoma (SCC), the second most common skin cancer. But when a tumor comes with more aggressive features, cutting it out doesn’t always guarantee it stays gone, and until now, doctors have had few tools to lower that risk afterward.
That may be starting to change. As reported by Dermatology Times, a large clinical trial found that giving the immunotherapy drug cemiplimab (Libtayo) for a year after surgery significantly lowered the odds of high-risk SCC returning, compared with a placebo.
What the Trial Found
The trial, known as C-POST, gave 415 patients with high-risk cutaneous SCC either cemiplimab or a placebo for a year after their surgery and radiation therapy. Patients on cemiplimab were roughly 70 percent less likely to see their cancer return during the study, a notably strong result for a group already considered high risk for recurrence.
Who This Trial Applies To
C-POST specifically enrolled patients whose tumors had features linked to a higher chance of coming back or spreading. Dermatologists reviewing the results caution against assuming every SCC patient would see the same benefit. A separate trial testing a different immunotherapy drug in a broader patient group didn’t show the same results, which is a reminder that not every case qualifies. That distinction is worth a real conversation with your own board-certified dermatologist.
Where This Leaves Patients
For people who’ve faced an aggressive SCC diagnosis, having a treatment to consider after surgery, rather than surgery followed by watching and waiting, is a meaningful shift. It’s still not a decision to make solo. Ask your dermatologist whether your case matches the risk profile that made a difference in this study and keep up with regular self-checks in the meantime. Catching a recurrence early still makes the biggest difference in outcome.
